← Research ProtocolsARA-290 / Cibinetide
STUDIED EXPOSURE MAP / 2015
ARA-290 / Cibinetide
tested in research.
The actual doses, concentrations or exposure levels reported by the source — kept attached to route, population, timeframe and evidence type.
HUMAN / PHASE 2MOLECULAR MEDICINESTUDIED EXPOSURE ≠ RECOMMENDED DOSE
STUDIED EXPOSURE / SOURCE DATANumbers below describe this research source only.
4 mg
SC · once daily · 28 days
Context: The 4 mg exposure is specific to this published phase-2 study and should not be interpreted as a recommended regimen.
NOT A DOSING GUIDEENHANCED is reporting what researchers administered or tested. It does not convert these numbers into a personal dose, reconstitution plan, cycle, titration schedule or recommendation.
SOURCE / MOLECULAR MEDICINE
ARA 290 improves metabolic control and neuropathic symptoms in patients with type 2 diabetes
Study design and tested exposure are separated from recommendation. Route and population stay visible so the numbers cannot be read without context.
2015
01 / DESIGNRandomized phase-2 placebo-controlled study
02 / POPULATION / MODELPeople with type 2 diabetes and painful neuropathy
03 / ROUTESubcutaneous · self-administered
04 / TIMEFRAME28 days
05 / PRIMARY QUESTIONMetabolic and neuropathic symptom measures
It supports a factual statement about the exposure tested in this research source. It does not establish that the same exposure is appropriate, effective or safe outside that source.
Tissue-protective and inflammatory-signalling research
Study exposure ≠ personal protocol. Animal doses are never converted to human-equivalent amounts here. IV, topical, oral, intranasal and subcutaneous exposures are not treated as interchangeable.